Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE TriStar Wellness Solutions
WESTPORT, Conn., Feb. 25, 2014 /PRNewswire/ -- TriStar Wellness Solutions®, Inc. (OTCQB: TWSI), a health and wellness company that targets opportunities in the self-care and professional marketplace, is pleased to announce that due to the rapid incremental sales growth on the HemCon hemostatic antibacterial woundcare line in the professional hospital market, the company has decided to accelerate the national expansion of their dental product line in North America. A reported ten million third molars (wisdom teeth) alone are extracted from approximately 5 million people in the United States each year at an annual cost of over $3 billion.
HemCon Medical Technologies Inc., a wholly owned subsidiary of TWSI located in Portland, OR, is a leading global developer of advanced medical products based on the unique raw material chitosan, a purified derivate of shrimp shells, which has application worldwide in battlefield trauma care, emergency medicine, acute care hospitals, dental practices and first aid.
This new release of the oral woundcare line will improve accessibility for the large oral surgeons, periodontist and dentists population to benefit from this cutting edge technology, and allow them to achieve the best possible patient care. The campaign will include direct marketing and online elements to increase awareness of this innovative oral wound dressing that protects the oral tissue with a physical barrier, and provides pain relief following tooth extractions and other surgical procedures.
Also fueling additional growth in the hospital cardiac catheterization labs is a recent randomized study1, published January 25, 2014 in the Journal of Vascular Medicine and Surgery, which compares the efficacy of the HemCon Patch to that of manual compression in percutaneous angioplasty procedures at Okayama University Hospital, Japan. This study demonstrated the use of the HemCon product significantly reduced time to hemostasis without any complications and confirms the dramatic improvement of patient outcomes when implementing a hemostatic HemCon solution.
"These activities and successes strengthen the positioning of the HemCon product portfolio and support its application and implementation across the continuum of care in varying medical settings." said Bill Shields, HemCon's Sr. Vice President of Sales and Business Development, "The research continues to build our deep reserve of clinical verification that underlies the effectiveness of our products".
1 Oozawa S, Akagi T, Sano S (2014) A New Hemostasis Tool after Percutaneous Angioplasty: The Hemcontm Pad Hemostasis Device. J Vasc Med Surg 2: 125. doi: 10.4172/2329-6925.1000125
About HemCon Medical Technologies
HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore. With a 36,000 sq. ft. state of the art manufacturing facility, the Company has additional commercial operations in Ireland and the Czech Republic. For more information, please visit www.hemcon.com.
About TriStar Wellness Solutions
TriStar Wellness Solutions®, Inc. (TWSI) is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beauté de MamanTM brand of women's health products. Additional information is available at www.tstarwellness.com.
This press release for TriStar Wellness Solutions®, Inc. contains forward-looking statements. Generally, you can identify these statements because they use words like "anticipates," "believes," "expects," "future," "intends," "plans," and similar terms. These statements reflect only our current expectations. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy and actual results may differ materially from those we anticipated due to a number of uncertainties, many of which are unforeseen, including, among others, the risks we face as described our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements which apply only as of the date of this press release. To the extent that such statements are not recitations of historical fact, such statements constitute forward-looking statements that, by definition, involve risks and uncertainties. In any forward-looking statement where we express an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation of belief will be accomplished.
Tel: (503) 245-0459
©2012 PR Newswire. All Rights Reserved.